Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint

Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader